search
Back to results

ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination (DIAGRAM)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 4
Locations
Indonesia
Study Type
Interventional
Intervention
GLIMEPIRIDE + METFORMIN
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

40 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Type 2 diabetes mellitus patients
  • Patients with HbA1c >or= 7.0% and < 10.0%
  • Patients not currently treated with any oral antidiabetic drugs (OADs)

Exclusion criteria:

  • Participation in other investigational Clinical Trial
  • Current temporary insulin treatment: gestational diabetes, pancreas cancer, surgery etc.
  • Women who are pregnant and lactating
  • Type 1 diabetes mellitus patients
  • Treatment with antihypertensive Angiotensin-Converting Enzyme (ACE)-Inhibitors and/or Angiotensin II Receptor Blocker (ARB) or has just stopped treatment for less than two months
  • Treatment with lipid lowering agent statins or has just stopped treatment for less than two months
  • Known hypersensitive to any of the excipients of Amaryl-M, sulphonylureas, sulfonamides or biguanide
  • Patients with active smoking or history of smoking cessation less than 2 months
  • Patients with history of severe hepatic dysfunction
  • Patients with serum creatinine >or= 1.5 mg/dL (male) and >or= 1.4 mg/dL (female)
  • Patients with congestive heart failure requiring pharmacologic treatment
  • Treatment with antifungal agent especially Miconazole

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sites / Locations

  • Sanofi-Aventis Administrative Office

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Amaryl-M (Glimepiride + Metformin)

Arm Description

Glimepiride 1 mg and metformin 250 mg are the active ingredients of Amaryl-M 1/250 mg film coated tablets. Starting dosage is 1 tablet per day, then dosage titration will be based on the result of patient FBG test.

Outcomes

Primary Outcome Measures

Adiponectin and Asymmetric Dimethylarginine (ADMA) plasma level changes

Secondary Outcome Measures

Change in adiponectin and Asymmetric Dimethylarginine (ADMA) plasma levels
Pulse Wave Velocity (PWV) change
Change in Fasting Blood Glucose (FBG)
Change in glycosylated hemoglobin (HbA1c)
Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Homeostatic Model Assessment (HOMA-β)
Change of Tumor Necrosis Factor- Alfa (TNF-Alfa)

Full Information

First Posted
September 16, 2010
Last Updated
April 2, 2012
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT01204580
Brief Title
ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination
Acronym
DIAGRAM
Official Title
ADIponectin and ADMA Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination (Amaryl-M)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2012
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
March 2012 (Actual)
Study Completion Date
March 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi

4. Oversight

5. Study Description

Brief Summary
Primary Objective: To evaluate the change in plasma levels of adiponectin and Asymmetric Dimethylarginine (ADMA) in type 2 diabetes patients after 12 weeks of treatment with Amaryl-M Secondary Objectives: To assess the role of Amaryl-M in the change of plasma levels of adiponectin and ADMA in type 2 diabetes patients after 8 weeks of therapy To evaluate the brachial-ankle pulse wave velocity (baPWV) change after 8 and 12 weeks of therapy with Amaryl-M To evaluate the efficacy of Amaryl-M in the improvement of patients glycemic level (Fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c)) To evaluate the change of Tumor Necrosis Factor - Alfa (TNF-Alfa) after 12 weeks of therapy with Amaryl-M To evaluate the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) change after 12 weeks of therapy with Amaryl-M To evaluate the HOMA-β change after 12 weeks of therapy with Amaryl-M To evaluate the relationship between adiponectin and ADMA level with FBG or HbA1c level
Detailed Description
The clinical trial will consist of 2 weeks of selection followed by a 12 weeks (3 months) of treatment period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Amaryl-M (Glimepiride + Metformin)
Arm Type
Experimental
Arm Description
Glimepiride 1 mg and metformin 250 mg are the active ingredients of Amaryl-M 1/250 mg film coated tablets. Starting dosage is 1 tablet per day, then dosage titration will be based on the result of patient FBG test.
Intervention Type
Drug
Intervention Name(s)
GLIMEPIRIDE + METFORMIN
Other Intervention Name(s)
Amaryl-M
Intervention Description
Pharmaceutical form: film coated tablet Route of administration: oral Dose regimen: 1 tablet of 1/250 mg per day
Primary Outcome Measure Information:
Title
Adiponectin and Asymmetric Dimethylarginine (ADMA) plasma level changes
Time Frame
from baseline to end of Clinical Trial (12 weeks)
Secondary Outcome Measure Information:
Title
Change in adiponectin and Asymmetric Dimethylarginine (ADMA) plasma levels
Time Frame
at week 8
Title
Pulse Wave Velocity (PWV) change
Time Frame
at week 8 and week 12
Title
Change in Fasting Blood Glucose (FBG)
Time Frame
At week 2, 4, 8 and 12
Title
Change in glycosylated hemoglobin (HbA1c)
Time Frame
at week 12
Title
Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Homeostatic Model Assessment (HOMA-β)
Time Frame
At week 12
Title
Change of Tumor Necrosis Factor- Alfa (TNF-Alfa)
Time Frame
At week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Type 2 diabetes mellitus patients Patients with HbA1c >or= 7.0% and < 10.0% Patients not currently treated with any oral antidiabetic drugs (OADs) Exclusion criteria: Participation in other investigational Clinical Trial Current temporary insulin treatment: gestational diabetes, pancreas cancer, surgery etc. Women who are pregnant and lactating Type 1 diabetes mellitus patients Treatment with antihypertensive Angiotensin-Converting Enzyme (ACE)-Inhibitors and/or Angiotensin II Receptor Blocker (ARB) or has just stopped treatment for less than two months Treatment with lipid lowering agent statins or has just stopped treatment for less than two months Known hypersensitive to any of the excipients of Amaryl-M, sulphonylureas, sulfonamides or biguanide Patients with active smoking or history of smoking cessation less than 2 months Patients with history of severe hepatic dysfunction Patients with serum creatinine >or= 1.5 mg/dL (male) and >or= 1.4 mg/dL (female) Patients with congestive heart failure requiring pharmacologic treatment Treatment with antifungal agent especially Miconazole The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Sanofi-Aventis Administrative Office
City
Jakarta
Country
Indonesia

12. IPD Sharing Statement

Learn more about this trial

ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination

We'll reach out to this number within 24 hrs